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Abstract
Background: Conjugated linoleic acid (CLA), a naturally occurring fatty acid found in ruminant
products such as milk and beef, has been shown to possess anti-cancer activities in in vivo animal
models and in vitro cell culture systems. In human breast cancer, the overall duration of estrogen
exposure is the most important risk factor for developing estrogen-responsive breast cancer.
Accordingly, it has been suggested that estrogen exposure reduces apoptosis through the up-
regulation of the anti-apoptosis protein, Bcl-2. Bcl-2, an anti-apoptotic protein, regulates apoptosis
and plays a crucial role in the development and growth regulation of normal and cancerous cells.
Our research interest is to examine the effects of CLA on the induction of apoptosis in human
breast tissues.
Methods: The localization of Bcl-2 in both normal and cancerous human breast tissues was
determined by immunohistochemical staining and the Bcl-2 protein expression was tested by
western blot analysis. Co-culture of epithelial cells and stromal cells was carried out in the presence
or absence of CLA to evaluate apoptosis in the context of a cell-cell interaction.
Results: The results showed that both normal and cancerous breast tissues were positive for Bcl-
2 staining, which was higher overall in mammary ducts but very low in the surrounding stromal
compartment. Interestingly, by quantifying the western blot data, basal Bcl-2 protein levels were
higher in normal breast epithelial cells than in cancerous epithelial cells. Furthermore, treatment
with 17β-estradiol (E2) stimulated growth and up-regulated Bcl-2 expression in estrogen
responsive breast epithelial cells; however, these carcinogenic effects were diminished by either
CLA or 4-Hydroxytamoxifen (Tam) and were suppressed further by the combination of CLA and
Tam. In both one cell type cultured and co-culture systems, CLA induced cell apoptosis in ERα
transfected MDA-MB-231 cells but not in the wild type MDA-MB-231 cells.
Conclusion: These data, therefore, demonstrate that ERα plays important roles in CLA induced
apoptosis in human breast tissues.
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Background
CLA is produced by rumen fermentation of linoleic acid
and is deposited in the subcutaneous fat and intramuscu-
lar fat layer in beef cattle; it also is present in dairy milk fat
[1]. There are several CLA isomers in ruminant-produced
foods, among them c9,  t11-CLA and t10,  c12-CLA are
more potent against tumor cell growth in vitro [2]. Fur-
thermore, rats fed CLA-enriched butter fat had reduced
mammary cancer risk [2]. Studies also showed that beef
CLA isomers even when associated with other beef fatty
acids reduce human cancer cell growth [3] and beef tallow
increases the potency of CLA against mouse mammary
tumor metastasis [4]. CLA studies in our laboratory [5-7]
demonstrated the anti-tumor effect of CLA (I) on angio-
genesis by suppression of the predominant vascular
endothelial growth factor (VEGF) isoforms, VEGF 121
and 165, and mRNA expression in a human breast cancer
cell line; (II) via up-regulation of the estrogen-regulated
cancer suppressor gene, protein tyrosine phosphatase γ
(PTPγ) in human breast cells; and (III) by modulation of
prostaglandin E2 (PGE2) signaling in canine mammary
cells.
Potential modulation of apoptosis by anti-cancer agents is
of interest for several reasons. Apoptosis, programmed
cell death, is thought to play a key role in the development
and growth regulation of normal and cancerous cells.
Consequently, dysregulation of apoptosis can result in
carcinogenesis [8]. The regulation of apoptosis involves a
large set of proteins including Bcl-2, an anti-apoptotic
protein [8]. In human breast cancers, about 75% of breast
cancers are estrogen receptor α (ERα) positive. Estrogens
cause initiation, promotion, and progression of these
tumors. E2 is the most abundant circulating endogenous
estrogen [9,10]. In the rat model, higher Bcl-2 expression
is detected in mammary epithelial cells when animals are
treated with E2 [11]. The anti-estrogen tamoxifen is the
most frequently prescribed drugs for estrogen responsive
breast cancer patients and also is recommended for
women at high risk of developing breast cancer [12].
Tamoxifen therapy generally is well tolerated and leads to
prolonged cancer-free survival and decreased mortality
even in patients with ER-positive metastatic tumors
[13,14]. However, the development of tamoxifen resist-
ance and the incidence of developing endometrial cancer
after five-year tamoxifen therapy is a critical issue [12,15].
Updated data from the Arimidex, Tamoxifen, alone or in
Combination (ATAC) trial showed that the aromatase
inhibitor appeared to be superior to tamoxifen in post-
menopausal women with ER-positive breast cancer [16].
Nevertheless, aromatase inhibitors cause different side
effects compared with those of tamoxifen, and the greater
level of the toxicity versus the efficacy of aromatase inhib-
itors needs to be investigated further [17]. Thus, the Amer-
ican Society of Clinical Oncology (ASCO) Health Services
Research Committee recommends that patients intolerant
to aromatase inhibitors should receive tamoxifen. The
concern in using endocrine therapy for chemopreventive
and/or chemotherapeutic purposes guided us to investi-
gate naturally existing compounds in food that possess
anticancer activity, such as CLA. Daily consumption of
CLA from ruminant-based foods for cancer prevention
will be less likely to raise concerns about toxicity. How-
ever, more recent data raised the concern about safety
issue of CLA. Dietary CLA, mainly t10, c12-CLA, induced
insulin resistance and increased plasma insulin levels in
both normal and obesity mice, and more important, sim-
ilar results have been reported in recent clinical trials [2].
It has also been demonstrated that high level of t10, c12-
CLA induced liver steatosis in mice [2]. Thus use this iso-
mer in the clinical need to be very cautious.
It has been theorized that the paracrine signals produced
by surrounding stromal cells plays a crucial role in modu-
lating malignant epithelial cells progression [18,19].
Studies suggest that CLA is incorporated, stored in stromal
cells, and CLA affect cancer progression [2]. CLA and
human breast cancer study revealed that dietary CLA
intake was associated with the regulation of estrogen
receptor expression in vivo [20]. CLA has been found to
reduce the risk of developing an estrogen receptor-nega-
tive tumor in premenopausal women, which may lead to
a better therapeutic outcome for breast cancer patients as
their cancer will be likely responsive to anti-estrogen ther-
apy [20]. Based on this epidemiological finding, we
hypothesize that CLA will exert anti-cancer activities in
ERα-positive breast tumors. In this study, we examined
the role of ERα in CLA-induced apoptosis in human
breast epithelial cells and the possible involvement of
apoptotic marker, Bcl-2, on CLA-mediated apoptosis.
Methods
Reagents
t10, c12-CLA (> 98% pure), the CLA isomer used in this
study, was purchased from Matreya, Inc. (Greenland, NH)
and a CLA stock solution was prepared as described previ-
ously [21]. For the steroid hormone study, we used Dex-
tran-Coated Charcoal (DCC, Dextran T-70; Pharmacia;
activated charcoal; Sigma, St. Louis, MO) to remove ster-
oid hormones in the fetal bovine serum (FBS, GibcoBRL,
Bethesda, MD). We then added the CLA to medium with
the DCC-treated FBS. 4-Hydroxytamoxifen (Tam),
docetaxel and 17β-estradiol (E2) were purchased from
Sigma (St. Louis, MO).
Immortalized cell line
MCF-7 and MDA-MB-231 cells were purchased from
American Type Culture Collection (ATCC, Manassas, VA).
MDA-MB-231-ERα cells (MDA-MB-231 cells stably trans-
fected with ERα) were a gift from Dr. Robert BrueggemeierBMC Cancer 2008, 8:208 http://www.biomedcentral.com/1471-2407/8/208
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at the College of Pharmacy, The Ohio State University. All
cell lines were cultured in phenol-red free high-calcium
Dulbecco's Modified Eagle's Medium and Ham's F12
Medium (DMEM/F12, 1.05 mM CaCl2) supplemented
with 5% fetal bovine serum (FBS) in 75 cm2 flasks and
incubated in a humidified incubator (5% CO2, 95% air,
37°C). The medium was renewed every two days.
Geneticin (500 mg/ml) was used every 2–3 passages for
maintenance and selection of MDA-MB-231-ERα cells.
Isolation of epithelial and stromal cells from human breast 
tissues
Normal (reduction mammoplastys) and malignant
human breast tissues were obtained through the Tissue
Procurement Program at The Ohio State University Hos-
pital in Columbus, Ohio. Tissues were placed in DMEM/
F12 and stored at 4°C. Isolation of epithelial and stromal
cells from human breast tissues and culture conditions
were described previously [5,6]. Briefly, tissues were
minced and digested in 0.1% collagenase I (GibcoBRL,
Bethesda, MD) supplemented with 5% FBS and antibi-
otic-antimycotic (100 unit/ml penicillin G sodium, 100
mg/ml amphotericin B) (GibcoBRL, Bethesda, MD) in
37°C humidified incubator (5% CO2: 95% air) overnight.
The digested mixture was centrifuged at 200 × g for 5 min
at 25°C. The cell pellet was re-suspended and allowed to
settle by gravity for 3 times. Stromal cells in the superna-
tant was then centrifuged at 200 × g for 5 min at 25°C and
the pelleted stromal cells were re-suspended in phenol
red-free high-calcium DMEM/F12 (1.05 mM CaCl2) sup-
plemented with 5% FBS. Cancer epithelial cells in the ini-
tial sedimented part were re-suspended in keratinocyte
serum free medium (Keratinocyte-SFM, 0.09 mM CaCl2)
(GibcoBRL) supplemented with bovine pituitary extract
(25 mg) and epidermal growth factor (10 μg). Normal
epithelial cells initial sedimented part were re-suspended
in low calcium DMEM/F12 (0.04 mM CaCl2) supple-
mented with Chelex-100 (Bio-Rad Laboratories, Rich-
mond, CA) -treated FBS (10%).
Treatment
Unless otherwise stated, cells were cultured in 5% DCC-
containing medium for two days followed by treatment
with CLA and/or E2 and/or Tam in the same medium for
three days. Finally, cells were harvested for performing
assays described in the following sections.
Co-culture system
Co-cultures of epithelial cells, MCF-7, MDA-MB-231 or
MDA-MB-231-ERα, with stromal cells, non-cancerous or
cancerous breast stromal cells, were performed using flat-
bottomed cell culture plates with the nucleopore polycar-
bonate membrane (0.4 μm pore size) of the cell culture
inserts. Culture condition for co-culture system was
described previously [5]. At the end of the treatment, epi-
thelial cells on the bottom chamber were subjected to
determine proliferation by caspase-3/7 activity assay and
Bcl-2 protein expression by western blot analysis as
described in the following sections.
Western blot analysis
At the end of the treatment period, cells were washed with
ice-cold PBS and then lysed with extraction reagent
(Pierce, Rockford, IL) and protease inhibitor (Pierce,
Rockford, IL) on ice. The performance of western blot
analysis was described previously [5]. Bcl-2 rabbit poly-
clonal antibody (sc-492, Santa Cruz, CA,) and β-actin goat
polyclonal antibody (sc-1615, Santa Cruz, CA,) were uti-
lized in this experiment.
Non-radioactive cell proliferation assay
Cell proliferation was quantified using the CellTiter 96™
AQueous assay (Promega, Madison, WI). This assay meas-
ures the amount of dehydrogenase enzymes found in met-
abolically active cells by adding enzyme substrate (MTS,
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and
electron coupling reagent (PMS, phenazine methosul-
fate). Briefly, 1 × 104 cells in 100 μl medium were seeded
and treated in 96-well plate. Then, 20 μl of MTS:PMS
(20:1) solution was added to each well. Plates were incu-
bated at 37°C for 1.5 hours and the color density was
checked every 30 minutes. Finally, optical density was
read at 490 nm (OD490 nm) using an ELISA plate reader.
Hoechst staining for apoptotic cells
Hoechst 33342, a DNA intercalating dye, fluoresces blue
when bound to DNA. For this part of the study, 2 × 104
cells were seeded on coverslips in triplicate. At the end of
treatment, cells on the coverslips were washed with 1X
PBS, fixed with 4% paraformaldehyde and stained with 5
mg/ml of Hoechst 33342 (Promega, Madison, WI) for 30
min at room temperature. The cells were washed again
with 1X PBS and mounted on glass slides. Under confocal
fluorescence microscopy (excitation 350 nm and emis-
sion 461 nm), apoptotic cells showed condensed chroma-
tin that was bright blue. Samples were stained and
counted in triplicate.
Immunohistochemical staining
The basal expression of Bcl-2 in 14 normal and 14 cancer-
ous human breast tissue samples were fixed, dehydrated,
embedded in paraffin, and sectioned for immunohisto-
chemical staining. Immunostaining was carried out using
the Vectastain Universal Quick kit (Vector Laboratories,
Burlingame, CA) followed by the DAB Substrate Kit for
Peroxidase (Vector Laboratories, Burlingame, CA) accord-
ing to manufacturer's instructions. After stopping the reac-
tion with water, the specimens were counterstained
(Hematoxylin, Vector Laboratories, Burlingame, CA) andBMC Cancer 2008, 8:208 http://www.biomedcentral.com/1471-2407/8/208
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mounted (Crystal/Mount, Biomeda, Foster City, CA).
Antibody against Bcl-2 is a rabbit polyclonal antibody
raised against a peptide mapping at the N-terminus of Bcl-
2 of human origin (sc-492 Santa Cruz, CA). To test the
specificity of Bcl-2 antibody, the primary antibody was
substituted with non-immune serum. Bcl-2 intensity was
evaluated by Allred scoring, which is a method that con-
veys estimated proportion score and intensity score [22].
Scores typically ranged from 0–8 and a score ranking
more than 3 (corresponds to ≥ 10% positive cells) was
defined as Bcl-2 positive [22].
Caspase-3/7 activity assay
Caspase-3 and -7 are members of the cysteine aspartic
acid-specific protease family and play important roles in
apoptosis in mammalian cells [23]. Each well contained
104 cells in 50 μl of medium were seeded and treated in 96
well-plates. At the end of treatment, caspase-3/7 activity
was quantified by Apo-ONE® homogenous caspase-3/7
assay according to the manufacturer's instructions
(Promega, Madison, WI). Briefly, 50 μl reagent (fluoro-
metric substrate: buffer in the ratio of 1:100) was added to
each well. Plates then were incubated at 37°C for 5 hours
and the intensity of the emitted fluorescence was deter-
mined with the use of a fluorescence spectrometer (excita-
tion 485 nm and emission 530 nm).
Statistics
The data for cell proliferation, Hoechst staining, caspase-
3/7 activity, and western blot of Bcl-2 protein expression
were presented as the mean ± standard deviation (SD) and
was analyzed using StatView® ANOVA unpaired t-test. p-
value less than 0.05 was considered to be statistically sig-
nificant. One cell group consisted of three replicate wells.
Results
CLA potentiates the effects of Tam in MCF-7 (ERα(+)) 
cells
Based on CLA concentration in normal physiologic
human serum (10–70 μM) and in humans who take CLA
long-term supplementation (50–350 μM), CLA concen-
trations used in in vitro studies has ranged from 12.5–250
μM, the mid-normal to supraphysiologic-pharmacologic
levels [24,25]. Our previous study showed that the effec-
tive dose range for inhibiting the proliferation of human
breast cancerous epithelial and stromal cells was 10–80
μM for three days and t10, c12-CLA was more potent than
c9, t11-CLA (unpublished data). Therefore, t10, c12-CLA
was used in the current study and a relatively lower but
effective dose, 40 μM of t10,  c12-CLA, was chosen to
investigate whether CLA potentiates the anti-proliferative
and pro-apoptotic effects of Tam. E2-stimulated cell
growth was suppressed by CLA or Tam, and the combina-
tion of CLA with Tam decreased the stimulative effects of
E2 in the ERα(+) human breast cancer cell line, MCF-7
even further (Fig. 1A). Moreover, we observed that the
combination of CLA and Tam caused more apoptosis
than treated alone in MCF-7 cells, as measured using
apoptotic indicators (Figs. 1B and 1C). These results sug-
gested that CLA may enhance the therapeutic efficiency of
Tam in estrogen-responsive human breast cancer patients.
CLA possesses greater apoptotic effect in ERα(+) breast 
cancer epithelial cells than in ERα (+) normal breast 
epithelial cells
Since CLA, a naturally occurring food component, will be
consumed by normal individuals as well, we examined
the effects of CLA on normal human breast epithelial
cells. We first utilized ERα(+) primary cultured normal
human breast epithelial cells (ERα(+) NEC) to examine
whether CLA also targets this type of cells. The estrogen
receptor positivity of the normal breast epithelial cells was
determined based on their ERα protein expression. MCF-
7 (ERα positive) and MDA-MB-231 (ERα negative) were
used as positive and negative control, respectively in the
determination of ERα expression in normal breast epithe-
lial cells. CLA was more effective in inducing apoptosis in
MCF-7 cells than in ERα(+) NEC (Fig. 1D). 10 μM of CLA
did not induce significant changes in apoptosis in ERα(+)
NEC. Thus, we used a higher dose of CLA (80 μM) and we
observed significant effects on apoptosis in ERα(+) NEC
(Fig. 1D). Next, we investigated whether CLA could sup-
press the mitogenic activity of E2 in ERα(+) NEC. CLA
treatment suppressed the ability of E2 to stimulate prolif-
eration (Fig. 1E) and CLA induced apoptosis in the pres-
ence of E2 (Fig. 1F). Although the proliferative response of
ERα(+) NEC to E2 appears to be small, we used Bcl-2
response to confirm that these cells are E2 responsive cells
(data not shown). These results suggested that CLA may
be chemopreventive in vivo.
CLA is more effective in inducing apoptosis in ERα(+) 
breast cells than in ERα(-) breast cells
In our in vitro system, neither CLA at 40 μM, Tam nor E2
caused considerable changes of cell growth or apoptosis
in the ERα(-) human breast cancer cell line, MDA-MB-
231, (Figs. 2A and 2B) or ERα(-) human primary cultured
normal breast epithelial cells (ERα(-) NEC) (Figs. 2C, D
and 2E). Based on this observation, we suspect that CLA
treatment resulted in decreased cell growth and increased
cell apoptosis is mainly mediated through ERα. To test
this possibility, we examined whether CLA exerted the
same effects in MDA-MB-231 stably transfected with ERα
(MDA-MB-231-ERα) cells as in MCF-7 cells. Our results
showed that CLA induced apoptosis in MCF-7 and MDA-
MB-231-ERα cells but did not have significant effects on
parental MDA-MB-231 cells (Figs. 3B and 3C).BMC Cancer 2008, 8:208 http://www.biomedcentral.com/1471-2407/8/208
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Effects of CLA on ERα(+) human breast cells Figure 1
Effects of CLA on ERα(+) human breast cells. (A) MTS assay, (B) Apo-ONE® homogeneous caspase-3/7 assay and (C) 
Hoechst staining for 3 days of treatment with CLA, Tam and E2 alone or combined with each other in MCF-7 cells. CLA stands 
for 40 μM t10, c12-CLA; Tam stands for 1 μM 4-Hydroxytamoxifen; E2 stands for 10 nM 17β-estradiol. CLA exerts combina-
tive effects with tamoxifen in MCF-7 cells. (D) Western blot analysis of basal ERα protein expression in MCF-7 and primary 
cultured ERα positive normal human breast epithelial cells (ERα(+) NEC). Equal amounts of isolated protein from both cell 
extracts were subjected to immunoblot with anti-ERα antibodies. β-actin was used as loading control. Histogram: Apo-ONE® 
homogeneous caspase-3/7 assay for the effects of treatment on apoptosis in MCF-7 and ERα(+) NEC for 3 days of treatment. 
(E) and (F) showed the effects of CLA and E2 on proliferation (MTS assay) and apoptosis (Hoechst staining) in ERα(+) NEC, 
respectively. 80 μM t10, c12-CLA; E2 stands for 10 nM 17β-estradiol. Bars represent mean ± SD, n = 3. *p < 0.05.
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Effects of CLA, Tam and E2 on cell proliferation and apoptosis of ERα negative human breast epithelial cells Figure 2
Effects of CLA, Tam and E2 on cell proliferation and apoptosis of ERα negative human breast epithelial cells. 
(A) and histogram in (C) are MTS assay for the effects of CLA, Tam and E2 for 3 days of treatment on cell proliferation of 
MDA-MB-231 and ERα negative normal human breast epithelial cells (ERα(-) NEC), respectively. (C) Western blot analysis of 
basal ERα protein expression in MCF-7 and primary cultured ERα negative normal human breast epithelial cells (ERα(-) NEC). 
Equal amounts of isolated protein from both cell extracts were subjected to immunoblot with anti-ERα antibodies. β-actin was 
used as loading control. Hoechst staining of (B) MDA-MB-231 and (E) ERα(-) NEC, and (D) Apo-ONE® homogeneous caspase-
3/7 assay of ERα(-) NEC after 3 days of CLA, Tam and E2 treatment. CLA stands for 40 μM t10, c12-CLA. Tam stands for 1 μM 
4-Hydroxytamoxifen; E2 stands for 10 nM 17β-estradiol. *p < 0.05 versus control. Docetaxel, the commonly used anti-cancer 
drug, was used as the positive control in the assay of cell proliferation and apoptotic activity.
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CLA inhibited E2 stimulation of Bcl-2 expression in ERα(+) 
breast cells
Since Bcl-2 is an anti-apoptotic protein, we would expect
to see higher Bcl-2 expression in cancerous human breast
tissues. To examine this speculation, immunohistochem-
ical staining for Bcl-2 expression was performed on 14
normal and 14 cancerous human breast tissue samples. In
this study, normal patients were younger (≤ 40 years of
age) than cancer patients (> 41 years of age) and based on
Allred scoring, all tissue samples were positive for Bcl-2
staining (score = 3) (Fig. 4A). Bcl-2 expression was local-
ized to cytoplasm and perinuclear area of cells mainly in
CLA induces apoptosis in ERα positive human breast cancer cell line Figure 3
CLA induces apoptosis in ERα positive human breast cancer cell line. (A) ERα protein expression was examined by 
western blot of whole cell lysate isolated from MCF-7, MDA-MB-231 (parental), and MDA-MB-231-ERα (ERα transfected 
MDA-MB-231). Equal amounts of isolated protein from cell extracts of all three cell lines were subjected to immunoblot with 
anti-ERα antibodies. β-actin was used as loading control. Effects of CLA on apoptosis of MCF-7, MDA-MB-231, and MDA-MB-
231-ERα were determined by Hoechst staining (B) and Apo-ONE® homogeneous caspase-3/7 assay (C). Bars represent mean 
± SD, n = 3. *p < 0.05 stands for control versus 40 μM t10, c12-CLA.
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Bcl-2 expression in human breast Figure 4
Bcl-2 expression in human breast. (A) Patients' information and Bcl-2 immunohistochemistry staining on both normal and 
cancerous breast tissues from human patients. (B) H&E staining and Bcl-2 immunohistochemistry staining showing dark to 
brown on one of the normal and one of the cancerous human breast tissues. Blue staining represents nuclei. (C) Western blot 
analysis of Bcl-2 protein expression in primary cultured human breast cells. CAEC stands for cancer epithelial cells; NEC stands 
for normal epithelial cells; CASC stands for cancer stromal cells; NSC stands normal stromal cells. Equal amounts of isolated 
protein from whole cell lysate were subjected to immunoblot with anti-Bcl-2 antibodies. β-actin was used as loading control.
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mammary ductal epithelium with slight staining of stro-
mal cells surrounding the mammary ducts (Fig. 4B).
Under the same magnification, Bcl-2 staining intensity
was greater in cancerous tissue compared with normal tis-
sues, which might be due to the larger cytoplasmic vol-
ume and larger mammary duct compartment in the
malignant samples. To quantify Bcl-2 expression, we iso-
lated epithelial cells and stromal cells from both cancer-
ous and normal breast tissues. Whole cell lysates were
electrophoresed and Bcl-2 protein expression was deter-
mined by western blot. In agreement with immunohisto-
chemical staining results, Bcl-2 protein was detected in
epithelial cells that lined the mammary duct but was very
weak in stromal cells (Fig. 4C). Interestingly, Bcl-2 expres-
sion was higher in primary cultured normal breast epithe-
lial cells (NEC) than in primary cultured cancerous
human breast epithelial cells (CAEC) (Fig. 4C). These
results suggest that Bcl-2 may be important in maintain-
ing normal breast function.
To evaluate whether the effect of CLA on Bcl-2 expression
was due to modulation of ERα, ERα(+) normal human
breast tissue and cells were treated with CLA, E2  or
CLA+E2. Bcl-2 expression was measured by immunohisto-
chemical staining and western blot. CLA treatment
decreased E2-stimulated Bcl-2 expression in tissues after
three days of treatment (Fig. 5A). This was confirmed by
quantification of western blot Bcl-2 protein results (Fig.
5B). Next, we examined whether CLA could potentiate the
anti-estrogenic effects of Tam in MCF-7 and ERα(+)
CAEC. CLA which is in combination with Tam further
suppressed E2-induced Bcl-2 protein expression in both
MCF-7 (Fig. 5C) and ERα(+) CAEC (Fig. 5C). Interest-
ingly, there are two bands of Bcl-2 were detected by west-
ern blot analysis in MCF-7 cells (Fig. 5C) whereas only
one band in ERα(+) CAEC (Fig. 5C). Different migration
of the same protein may be caused by the post-transla-
tional modification, such as phosphorylation. It has been
suggested that phosphorylation will stabilize Bcl-2 which
may lead to anti-apoptosis of the cell [26,27]. By contrast,
de-phosphorylation of Bcl-2 will sensitize cell to apopto-
sis inducing agent. Thus it is reasonable to speculate that
MCF-7 cells, with immortalized characteristic, will be
more resistance to apoptosis in comparison with ERα(+)
CAEC which is primary cultured from human breast tis-
sue.
Effects of stromal cells on CLA regulated Bcl-2 expression 
in human breast epithelial cells
We observed that CLA induced apoptosis in ERα(+) breast
cells but not in ERα(-) breast cells (Fig. 3). Studies have
shown that the local micro-environment is crucial for can-
cer progression, because cancer epithelial cells are sur-
rounded by various types of stromal cells [28]. The
interaction between epithelial cells and extracellular
matrix is important for cells to make life or death deci-
sions [29]. To address whether stromal cells can alter CLA-
induced apoptosis in ERα(+) and ERα(-) cancer epithelial
cells, breast cancer epithelial cell lines, MCF-7, MDA-MB-
231, or MDA-MB-231-ERα, were co-cultured with primary
human breast stromal cells isolated from normal (NSC)
or cancerous (CASC) tissues. After 7 days of CLA treat-
ment, apoptosis in breast cancer epithelial cell lines were
measured by caspase-3/7 activity. Apoptosis of co-cul-
tured MCF-7 cells was not changed in comparison with
MCF-7 cells cultured alone. CLA treatment induced apop-
tosis in MCF-7 cells cultured alone and stimulated further
apoptosis when these cells were co-cultured with stromal
cells (Fig. 6A). A similar pattern of response also was
shown in MDA-MB-231-ERα cells (Fig. 6C) but not in
MDA-MB-231 cells (Fig. 6B). In agreement with the
results in Figs. 6A–C, we observed that Bcl-2 protein was
significantly increased in co-cultured MCF-7 and MDA-
MB-231-ERα cells but not in MDA-MB-231 cells (Fig. 6D).
Furthermore, Bcl-2 expression was decreased in the co-
cultured cells treated with CLA. Our results suggest that
CLA may modulate the breast microenvironment by
blocking the interaction between malignant ERα(+) epi-
thelial cells and stromal cells; although CLA also induce
apoptosis of stromal cells (unpublished data), CLA did
not induce significant changes in apoptosis in co-cultured
MDA-MB-231 cells.
Discussion
CLA has anti-estrogenic effects that may correlate with 
reduced risk of ERα(-) negative breast cancer
Evidence from epidemiological studies has shown that the
duration of estrogen exposure is an important risk factor
for development of breast cancer. Estrogens are involved
in initiation, promotion, and progression of breast car-
cinogenesis [30]. It has been shown that CLA exerts little
to no inhibitory effect on MDA-MB-231 cells compared to
MCF-7 cells suggesting the possible involvement of anti-
estrogenic effects of CLA on human breast cancers
[24,31,32]. Using MCF-7 cells transiently transfected with
the estrogen responsive element (ERE), Tanmahasamut et
al. (2003) [24] demonstrated that CLA inhibited the pro-
moter's activity directly through the ERE. More recently,
Liu and Sidell (2005) [33] showed that CLA suppressed
phosphorylation of the estrogen receptor, which may
inhibit receptor-ERE interactions in MCF-7 cells. We
examined the anti-estrogenic effects of CLA on MCF-7,
MDA-MB-231, ERα(+) NEC and ERα(-) NEC (Figs. 1 and
2). CLA had anti-proliferative effects in MCF-7 and
ERα(+) NEC but not in MDA-MB-231 and ERα(-) NEC.
Potentiation of Tam by combination with CLA was
observed in MCF-7 cells. It was observed that CLA reduced
cell proliferation in normal mammary gland but did not
induce apoptosis of cells within the terminal end buds
and lobular epithelium in rats [34-36]. In contrast, CLABMC Cancer 2008, 8:208 http://www.biomedcentral.com/1471-2407/8/208
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CLA decreases E2 stimulated Bcl-2 protein expression in ERα(+) breast cells Figure 5
CLA decreases E2 stimulated Bcl-2 protein expression in ERα(+) breast cells. (A) Immunohistochemistry of Bcl-2 
staining (brown to dark) in ERα(+) normal human breast tissue for 3 days of treatment. (B) Western blot analysis of basal ERα 
protein expression in MCF-7 and ERα(+) NEC, and the effects of CLA and E2 on Bcl-2 protein expression in ERα(+) NEC for 
3 days of treatment. β-actin was used as loading control. (C) Western blot analysis of basal ERα protein expression in MCF-7 
and ERα positive human breast cancer epithelial cells (ERα(+) CAEC). And Bcl-2 protein expression in MCF-7 and ERα(+) 
CAEC was detected by western blot analysis after 3 days of treatment. CLA exerts combinative effects with Tam in decreasing 
E2 stimulated Bcl-2 protein expression in ERα(+) CAEC. CLA stands for 40 μM t10, c12-CLA; E2 stands for 10 nM 17β-estra-
diol.
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CLA induced apoptosis of breast cancer epithelial cells is associated with estrogen receptor α (ERα) in co-culture Figure 6
CLA induced apoptosis of breast cancer epithelial cells is associated with estrogen receptor α (ERα) in co-cul-
ture. MCF-7 (A), MDA-MB-231 (B), ERα transfected MDA-MB-231, and MDA-MB-231-ERα (C), were cultured alone or co-
cultured with normal human breast stromal cells (NSC), or co-cultured with cancerous human breast stromal cells (CASC). 
Cells were treated by t10, c12-CLA for 7 days and cell apoptosis of MCF-7 (A), MDA-MB-231 (B) or MDA-MB-231-ERα (C) 
was detected from each group separately by caspase-3/7 activity assay. (D) Bcl-2 protein expression of MCF-7, MDA-MB-231 
or MDA-MB-231-ERα was determined by western blot analysis. CLA stands for 40 μM t10, c12-CLA. Bars represent mean ± 
SD, n = 3. *p < 0.05 stands for t10, c12-CLA group comparison of caspase-3/7 activity; +p < 0.05 for control versus t10, c12-
CLA.
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induced apoptosis in mammary tumor cells and premalig-
nant rat mammary gland [37]. Our results showed that
although CLA also induced apoptosis in ERα(+) NEC, a
greater effect was observed in MCF-7 cells than in ERα(+)
NEC (Fig. 1D). We speculate that dietary long-term con-
sumption of CLA may have moderate chemopreventive
activities in healthy individuals. Furthermore, in breast
cancer patients, CLA also might have less of an effect on
normal parts of the mammary gland, resulting in a lesser
degree of cytotoxicity in these patients.
To ascertain the role of ERα in the anti-estrogenic effects
mediated by CLA, MDA-MB-231-ERα cells (ERα tran-
siently transfected MDA-MB-231) were treated with E2 or
E2+CLA. CLA exerted anti-estrogenic effects in MCF-7 and
MDA-MB-231-ERα cells but treatment did not induce
considerable effects in MDA-MB-231 cells. E2 treatment
inhibited the growth of MDA-MB-231-ERα and CLA
counteracted E2-induced growth inhibitory effect (unpub-
lished data). According to these and results shown in Fig.
3, we expect that the anti-cancer activities of CLA will be
more effective in ERα(+) breast cancer patients than those
with ERα(-) breast cancers. This might explain epidemio-
logical findings showing that CLA intake may be corre-
lated with reduced risk of having an estrogen receptor
negative cancer in premenopausal breast cancer patients
[20].
Mechanisms of the anti-estrogenic effects of CLA
The carcinogenic effects of estrogens in breast cancer
include the stimulation of breast tissue growth and the
protection of cells from apoptosis [30]. A higher prolifer-
ative rate in tumors has been correlated with metastasis,
death from neoplasia, low disease-free survival rates, and
low overall survival rate in human cancer models [31].
Immunohistochemical staining studies suggested that
Bcl-2 expression is linked to hormonal regulation in
human breast cancers [38]. Interestingly, several studies
showed Bcl-2 protein expression in normal as well as
hyperplastic and neoplastic breast epithelial cells [38-40].
In agreement with these findings, our results showed that
Bcl-2 protein is expressed in both cancerous and normal
human breast tissues (Fig. 4). In normal breast tissue sam-
ples, 12 out of 14 were from patients under 40 years of
age; 10 were diagnosed as macromastia and the remaining
four were diagnosed as hypertrophy (Fig. 4). Accordingly,
we speculate that Bcl-2 may be important to maintain
mammary gland function in these normal patients and
Bcl-2 may be involved in the occurrence of mammary
hypertrophy and mammary macromastia. It has been sug-
gested that cells express Bcl-2 are immature and may be
part of the stem-cell subpopulation in normal mammary
gland [40]. Bcl-2 is important for maintenance and devel-
opment of normal mammary gland. However, Bcl-2
expression is increased when cell proliferation in tissues is
dysregulated in hyperplastic and neoplastic disorders. Bcl-
2 localization in normal breast tissue may be related to
the origin of malignant breast disease [40]. Upon E2 stim-
ulation, Bcl-2 protein was increased in ERα(+) normal as
well as cancerous human breast (Fig. 5). We have
observed that CLA also blocks the estrogenic effects of
environmental hormones such as Zeranol, a nonsteroidal
agent with estrogenic activity used as a growth promoter
in the US beef and veal industries (unpublished data).
Taken together, the results suggest that CLA is an excellent
candidate for prevention and therapy of estrogen respon-
sive breast cancer.
CLA blocks the epithelial-stromal interaction in the 
ERα(+) but not ERα(-) human breast microenvironment
From experimental cancer models, the extracellular
microenvironment has been demonstrated to influence
tumor formation, the rate of cellular proliferation, the
ability of the cancer cells to metastasize and the extent of
invasiveness. In many cancers, the influences of the
microenvironment are mediated in part by paracrine sig-
naling between epithelial cancer cells and the surround-
ing stromal cells [41,42]. Although Bcl-2 is expressed
highest in malignant epithelial cells, stromal cells also
express Bcl-2 but in lesser amounts, which may indicate
both autocrine and paracrine effects of Bcl-2 in the tumor
microenvironment (Fig. 4). CLA induced more apoptosis
in MCF-7 and MDA-MB-231-ERα cells when those cells
were co-cultured with stromal cells suggesting that the
presence of stromal cells is important in CLA induced
apoptosis in ERα(+) cancer cells which support the theory
that CLA is incorporated and stored in stromal cells to
affect cancer progression [2]. It appeared that CLA was
able to interrupt this paracrine signal (Figs. 6A and 6C).
However, the involvement of stromal cells did not alter
the effects of CLA in MDA-MB-231 cells (Fig. 6B).
Although CLA possesses apoptotic effect in both normal
and cancerous stromal cells (data not shown), cancerous
ERα negative breast epithelial cells may acquire independ-
ent self-regulation from the surrounding stromal com-
partment.
Efficacy of CLA in breast cancer chemoprevention
Preclinical studies [43,44] showed promising anti-mam-
mary tumor activity in mouse (~3.5 mg/20 g mouse · d)
and rat models (~13 mg/275 g rat · d) that are equivalent
to the effective concentration in humans (~2.8 g CLA/70
kg · d). Epidemiological studies have demonstrated that
a diet composed of CLA-rich foods (204 mg CLA/day),
particularly cheese, may protect against breast cancer in
postmenopausal women [45]. More recently, another
study showed that CLA intake (134–155 mg CLA/day)
was not related to overall breast cancer risk, however, the
risk of estrogen receptor (ER)-negative breast cancer
among premenopausal women was reduced [20]. It isBMC Cancer 2008, 8:208 http://www.biomedcentral.com/1471-2407/8/208
Page 13 of 14
(page number not for citation purposes)
clear that women consume ~100 times less than the
amount of CLA estimated to provide protection. A moder-
ate but effective influence may occur after low level long
term consumption of CLA. Since CLA is a natural by-prod-
uct of rumen fermentation and is found in foods derived
from ruminants, consumption of CLA from foods for the
purposes of chemoprevention likely will not affect the
safety of consumers. It is interested to note that special
diet of cow is able to increase CLA in milk fat [2]. Whether
CLA will cause any toxic effects on these cows? We specu-
late that CLA will be less likely to induce cell apoptosis in
the udder of these cows because CLA in the circulation
will not reach the doses used in in vitro cell culture models
nor the concentrations of CLA-enriched diet in animal
studies.
Conclusion
We investigated the role of ERα in CLA induced apoptosis
in human breast tissue. Treatment of ERα(+) breast cancer
cells and tissue with E2 led to stimulated growth and up-
regulated Bcl-2 expression; however, these carcinogenic
effects were diminished by either CLA or Tam and were
suppressed further by the combination of CLA and Tam.
By contrast, ERα(-) cells and tissue failed to respond to the
treatments. This result was further confirmed by the trans-
fection of ERα into these cells which restored their
response to CLA. Therefore, our findings demonstrate that
CLA exert anti-estrogenic effects and ERα plays important
roles in CLA induced apoptosis in human breast tissues.
Future study examine the knock down of ERα in MCF-7
cells to confirm the loss of response of these cells to CLA
are crucial to support the proposed mechanism – ERα
plays important role in CLA's anti-cancer activity.
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